Celltrion

Following the successful deal closure in April with Express Scripts, one of the top three PBMs, to list ‘Zymfentra’ on the formulary, Celltrion has received numerous inquiries from shareholders and analysts about the status of listing agreements with the other two PBMs. 

We are pleased to announce that on July 30 , 2024(EST), we finalized a successful deal with another top-three PBM and wish to share this news preliminarily with our shareholders and analysts through our website. 

While we are excited to share the details of this agreement, as provided below, we must adhere to contractual obligations, which prevent us from disclosing the name of the PBM at this time.

• Celltrion has signed a contract with Express Scripts to include Zymfentra, the world's first and only subcutaneous infliximab, in their formulary within two weeks of the product's launch in March. 

  Following this agreement, we also secured a deal to list Zymfentra with another top three PBM as of July 30, 2024.

• In addition, Celltrion aims to sign an agreement shortly with the remaining top three PBM for the formulary inclusion of Zymfentra. This would allow Zymfentra to be listed on the formularies of all three major PBMs, which collectively cover about 80% of the US insurance market. Achieving this would provide a strong foundation for the prescription growth of Zymfentra in the largest pharmaceutical market in the world. 

• Our focus goes beyond PBM contract closures; we are committed to turning this achievement into actual sales. We will continue to keep you informed of related news through various channels. 

We extend our sincere gratitude for your unwavering support and confidence in Celltrion.